Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural requirements for B2-agonists with improved degradation stability.

A Dendorfer1, M Wagemann, S Reissmann

  • 1Institute of Pharmacology, Medical University of Lübeck, Germany. dendorfe@medinf.mu-luebeck.de

Immunopharmacology
|December 30, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023.

Rhinology·2023
Same author

Chemical and mechanical activation of resident cardiac macrophages in the living myocardial slice ex vivo model.

Basic research in cardiology·2022
Same author

Effects of controlled ovarian stimulation on vascular barrier and endothelial glycocalyx: a pilot study.

Journal of assisted reproduction and genetics·2021
Same author

A practical guide for investigating cardiac physiology using living myocardial slices.

Basic research in cardiology·2020
Same author

Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.

Nature medicine·2020
Same author

Medium-chain fatty acids modulate myocardial function via a cardiac odorant receptor.

Basic research in cardiology·2017

Researchers developed new bradykinin (BK) analogues that resist degradation by kininases, maintaining potent activity at the bradykinin B2-receptor. These modified peptides offer a promising avenue for therapeutic applications requiring stable BK agonism.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Bradykinin (BK) is a peptide rapidly degraded by kininases, limiting its therapeutic use.
  • Previous attempts to stabilize BK often resulted in reduced agonistic activity.
  • Developing degradation-resistant BK agonists for the bradykinin B2-receptor remains a challenge.

Purpose of the Study:

  • To identify novel structural modifications for creating degradation-resistant bradykinin B2-receptor agonists.
  • To evaluate the efficacy and stability of modified BK analogues against rat serum kininases.

Main Methods:

  • Synthesized various BK analogues with modifications including N-terminal/C-terminal changes, amino acid substitutions, and cyclization.
  • Assessed receptor affinity and agonistic activity using a bradykinin B2-receptor model (FURA-stained rat fibroblasts).

Related Experiment Videos

  • Investigated kinin inactivation in rat serum using selective inhibitors for angiotensin I-converting enzyme (ACE), carboxypeptidase N (CPN), aminopeptidase P (APP), and aminopeptidase M (APM).

    • Main Results:

    • Analogues from phyllokinin and cyclic peptides lacked receptor affinity.
    • Specific modifications like D-Arg0, D-N-methyl-Phe7, dehydro-Phe5, and certain erythro-substituted amino acids enhanced stability against specific kininases (APP, ACE, CPN).
    • Two novel derivatives, D-Arg0-[Hyp3, Thi5, epsilonSer(betaPh)8]-BK and D-Arg0-[Hyp3, Thi5, epsilonAbu(betaPh)8]-BK, demonstrated potent B2-agonism and significant resistance to rat serum kininases.

    Conclusions:

    • Structural modifications can yield bradykinin analogues with enhanced stability against enzymatic degradation.
    • The identified derivatives represent potent and stable bradykinin B2-receptor agonists.
    • These findings pave the way for developing more effective bradykinin-based therapeutics.